

## Sexual dysfunction in middle-aged women: a multicenter Latin American study using the Female Sexual Function Index

**AQ1** *Juan E. Blümel, MD, PhD, Peter Chedraui, MD, MSc, German Baron, MD, Emma Belzares, MD, Ascanio Bencosme, MD, Andres Calle, MD, MSc, Maria T. Espinoza, MD, Daniel Flores, MD, Humberto Izaguirre, MD, MSc, Patricia Leon-Leon, MD, Selva Lima, MD, Edward Mezones-Holguin, MD, MSc, Alvaro Monterrosa, MD, Desire Mostajo, MD, MSc, Daysi Navarro, MD, PhD, Eliana Ojeda, MD, MSc, William Onatra, MD, MSc, Monique Royer, MD, PhD, Edwin Soto, MD, MSc, Soledad Vallejo, MD, and Konstantinos Tserotas, MD, for the Collaborative Group for Research of the Climacteric in Latin America (REDLINC)*

### Abstract

**Objective:** The purpose of this study was to assess the prevalence of sexual dysfunction (SD) and associated risk factors among middle-aged Latin American women using one validated instrument.

**Methods:** The Female Sexual Function Index (FSFI) was applied to 7,243 healthy women aged 40 to 59 years who were users of 19 healthcare systems of 11 Latin American countries. An itemized questionnaire containing personal and partner sociodemographic data was also filled out.

**AQ2**

**Results:** Mean  $\pm$  SD age of surveyed women was  $49.0 \pm 5.7$  years, with 11.6 years of schooling on average. There were 55.1% of women who were married, 46.8% who were postmenopausal, 14.1% who used hormonal therapy (HT), and 25.6% who were sexually inactive. Among those who were active ( $n = 5,391$ ), the mean  $\pm$  SD total FSFI score was  $25.2 \pm 5.9$  and 56.8% of them presented SD (FSFI total score  $\leq 26.55$ ), with a prevalence varying from 21.0% to 98.5% depending on the center. Centers were grouped in terciles (according to mean  $\pm$  SD prevalence). The tercile with higher SD prevalence (86.4%) compared with that with lower SD prevalence (32.2%) had significantly older women ( $49.5 \pm 5.3$  vs  $48.0 \pm 5.6$  y) with a higher rate of vaginal dryness (60.4% vs 40.8%) and older partners ( $53.0 \pm 6.9$  vs  $50.2 \pm 7.5$  y). Similarly, there was a significantly higher rate of married (68.5% vs 63.1%), postmenopausal (49.7% vs 39.3%), and HT-using women (23% vs 9.2%). There were no differences in regard to their health perception, history of oophorectomy, rape, and partner SD rate (27% vs 26.2%). The total FSFI score was significantly lower in the tercile with higher SD prevalence ( $22.0 \pm 5.0$  vs  $27.5 \pm 5.4$ ). Logistic regression analysis was used to determine the odds ratios (95% CIs) for the main risk factors associated with SD among those who were sexually active: bad lubrication, 3.86 (3.37-4.43); use of alternative menopausal therapies, 2.13 (1.60-2.84); partner SD, 1.89 (1.63-2.20); older women ( $>48$  y), 1.84 (1.61-2.09); bladder problems, 1.47 (1.28-1.69); HT use, 1.39 (1.15-1.68); negative perception of female health status, 1.31 (1.05-1.64); and being married, 1.22 (1.07-1.40). Protective factors were higher educational level (women), partner faithfulness, and access to private healthcare.

**AQ3**

**Conclusions:** The prevalence of SD in this middle-aged Latin America series was found to be high, varying widely in different populations. A decrease in vaginal lubrication was the most important associated risk factor. Differences in the prevalence of risk factors among the groups studied, several of which are modifiable, could explain the variation of SD prevalence observed in this study.

**Key Words:** Sexual dysfunction – Female Sexual Function Index – Menopause – Latin America.

**S**exuality is essentially a group of anatomical, physiological, and psychoaffective animal conditions that characterize each gender. However, among human

beings, sexuality is an aspect that addresses sex, identity and gender roles, erotism, pleasure, intimacy, reproduction, and orientation. Sexuality is influenced by the interaction of biological, psychological, social, economical, political, ethnical, legal historical, religious, and spiritual factors.<sup>1</sup>

Latin America is a mosaic of countries with different socioeconomical levels, ethnics, and political systems.<sup>2</sup> However, equal culture, religion (Catholic), and origin (mestizo: Spaniard/indigenous) is the framework that unites this population. The diversity of biological and sociocultural factors

Received February 11, 2009; revised and accepted March 11, 2009.

Financial disclosure: None reported.

Address correspondence to: Peter Chedraui, MD, MSc, Institute of Biomedicine, Facultad de Ciencias Médicas, Universidad Católica de Santiago de Guayaquil, PO Box 09-01-4671, Guayaquil, Ecuador.  
E-mail: peterchedraui@yahoo.com

could have different effects on female sexuality in several Latin American countries.

Human sexuality is a complex phenomenon that involves psychological and organic processes. Moreover, one must bear in mind that sexuality may also be affected by sociocultural changes, which are permanent occurrences within societies. Hence, the systematic study of sexuality data is very complex. A major improvement was an international consensus conference (*The International Consensus Development Conference on Female Sexual Dysfunctions*) and the development through this conference of the Female Sexual Function Index (FSFI), a test with psychometric properties, capable of assessing sexual function within various domains: desire, arousal, orgasm, pain, lubrication, and satisfaction.<sup>3,4</sup> The Spanish version of this tool has been validated among Latin American women aged 20 to 59 years.<sup>5</sup>

Recently, a network of Latin American researchers who are studying the climacteric has been established, allowing the performance of various multicenter studies and the generation of several important publications.<sup>6-10</sup> Within this scenario of a research network and current validated tools for assessing female sexuality, we carried out this cross-sectional study aimed to assess the prevalence of sexual dysfunction (SD) and associated risk factors among middle-aged Latin American women using one validated instrument, the FSFI.

## METHODS

### Participants

From November 2006 to February 2007, a cross-sectional study was carried out in 19 healthcare centers of cities with a population of more than 500,000 inhabitants in 11 Latin American countries (see list of participating countries and investigators in Appendix 1). Using statistical software (EPI-INFO 6.04; Centers for Disease Control and Prevention, Atlanta, GA), a minimal sample size of 380 per center was calculated, considering that each center covered an estimated population of 50,000 women<sup>11</sup> and assuming that 50% of the surveyed population would present SD<sup>12,13</sup> with an estimated 5% error and a 95% CI. To record all data, an itemized questionnaire was previously constructed and validated in 50 women before implementation at the centers affiliated with the Collaborative Group for Research of the Climacteric in Latin America (REDLINC) participating in this study known as the REDLINC III, aiming to assess sexuality and determine SD prevalence and related risk factors in middle-aged women. Healthy Hispanic women (nonblack) aged 40 to 59 years who were accompanying patients attending health centers were included. Pregnant women, women of indigenous populations, and those refusing to fill out the survey or incapable of understanding the items contained in it were excluded. Similarly, lesbian women were not included in this survey because this population requires the use of modified questionnaires to study their sexuality.<sup>14</sup>

Women fulfilling the inclusion criteria were requested to fill out the FSFI<sup>4</sup> and a general data questionnaire after being informed about the research, its purpose, the FSFI, and its

content. Participants were also asked to complete the Menopause Rating Scale (MRS). After consenting to participate and upon filling out the questionnaire, they received additional support. The research protocol for this study was reviewed and approved by the Bioethics Committee of the PROSAM Foundation, Santiago de Chile, Chile.

### Variables included in the general questionnaire

#### General data

General data were age (years), parity, REDLINC center number (city and country), menopause status (premenopause, perimenopause, or postmenopause), marital status, sexual status for the last 4 weeks (active or inactive), educational level (expressed in years of schooling), and accessed health-care system (free-minimal cost [ $<25\%$  of private consultation fee] or paid [paying more than the minimal cost]). Insufficient educational level (women or partner) was considered as 12 years or less of study.<sup>15</sup>

#### Lifestyle and other personal factors

Lifestyle and other personal factors included were smoking habit (current smoker, sometime smoker, or nonsmoker), church attendance, history of sexual abuse (rape), and current relationship (one partner). Women were asked about how they perceived their health status (and that of their partner). Those capable of performing daily routine activities were defined as healthy.<sup>16</sup>

#### Medical care and drug

The rate of women seeking psychiatric attention was assessed as well as the use of psychotropic drugs and hormonal therapy (HT)/alternative therapies for postmenopausal women.

#### Data related to partner

Partner age (years), years of schooling (total years), healthiness, presence of alcoholism, or SD (erectile or premature ejaculation) were assessed. Women were asked about male faithfulness. Alcoholism was defined as a chronic conduct disorder manifested by repeated and excessive alcohol consumption, which interferes with health, economic, or social relationships. Erectile dysfunction was defined as the persistent or recurrent incapacity to achieve or maintain an erection to allow satisfactory sexual intercourse,<sup>17</sup> whereas premature ejaculation was defined as the persistent or recurrent ejaculation after minimal sexual stimulation before, during, or shortly after penetration or before the individuals desire to do so.<sup>18</sup>

#### Menopause status definitions

For menopause status, the following definitions were used: premenopausal, women having regular menses; perimenopausal, irregularities more than 7 days from their normal cycle; and postmenopausal, no menses in the last 12 months.<sup>19</sup> Those with bilateral oophorectomy were considered as postmenopausal.

#### The FSFI

This instrument used to assess sexual function in the past 4 weeks is composed of 19 questions grouped in six domains or dimensions: desire (items 1 and 2), arousal (items 3-6),

AQ6

AQ7

AQ8

AQ4

AQ5

lubrication (items 7-10), orgasm (items 11-13), satisfaction (items 14-16), and pain (items 17-19). Each question has a Likert scale score varying from 0 to 5. Scores obtained in a particular domain are added and multiplied by a respective factor that homogenizes the influence of each dimension. The total FSFI score is the sum of all scores obtained in each domain.<sup>4</sup> A higher score indicates better sexuality. Participants obtaining a total FSFI score of 26.55 or less were defined as having SD.<sup>20</sup> For the purpose of this research, the validated FSFI Spanish version was used (Cronbach  $\alpha > 70\%$ ).<sup>5</sup>

### The MRS

The MRS is composed of 11 items assessing menopausal symptoms divided into three subscales: (1) somatic: hot flushes, heart discomfort, sleeping problems, and muscle and joint problems (items 1-3 and 11, respectively); (2) psychological: depressive mood, irritability, anxiety, and physical and mental exhaustion (items 4-7, respectively); and (3) urogenital: sexual problems, bladder problems, and dryness of the vagina (items 8-10, respectively). Each item can be graded by the participant from 0 (not present) to 4 (1 = mild, 2 = moderate, 3 = severe, 4 = very severe). For a particular individual, the total score for each subscale is the sum of each graded item contained in that subscale. The total MRS score is the sum of the scores obtained for each subscale. The MRS scale has been translated into more than 27 languages. For the purpose of this research, the Spanish version of the MRS was used,<sup>21</sup> which has been validated in Ecuador and Chile.<sup>22,23</sup> Validity of the Spanish version of the MRS has been confirmed through analysis of internal (Cronbach  $\alpha > 0.80$ ) and external reliability (significant retest correlation with Pearson's coefficient,  $P < 0.01$ ).<sup>23</sup>

### Statistical analysis

Statistical analysis was performed with EPI-INFO statistical software (versions 6.04 and 2000 [World Health Organization, Basel, Switzerland]). Results are expressed as mean  $\pm$  SD or percentages. Group comparisons for means were assessed with Student's *t* test, analysis of variance, or the Mann-Whitney test, according to homogeneity of measured variance with the Bartlett test. Percentage differences were evaluated with the  $\chi^2$  test. Centers were grouped (only sexually active) according to their SD prevalence (mean) and comparison between lowest and highest terciles performed. Logistic regression analysis was performed (EPI-INFO 2000) for the simultaneous assessment of several

variables influencing female sexual function in those sexually active (for the past 4 wk). For this, total FSFI score, as continuous variables, was transformed into a categorical score, now considered as women exhibiting scores of 26.55 or less. Menopausal symptoms comprising the MRS were categorized as not present (symptom score was 0) and present (score of 1 or higher). Independent variables (women and men) to be entered in the regression model were as follows: (for women) access to free health care, older age ( $\geq 48$  y, median), higher parity ( $> 2$ , median), lower educational level ( $\leq 12$  y), marital status (married or not), postmenopause status, smoking status, medication use (HT/alternatives for postmenopausal women, psychiatric drugs), history of sexual abuse (rape), church attendance, psychiatrist attention, female health perception, and menopausal symptoms, and (for men) partner age, lower educational level, alcoholism, healthiness, faithfulness, premature ejaculation, and erectile dysfunction. Entry of variables into the model was considered, with a 20% significance level, and the stepwise procedure was performed. A *P* value less than 0.05 was considered as statistically significant.

### RESULTS

A total of 7,243 healthy women aged 40 to 59 years who were users of 19 healthcare systems of 11 Latin American countries were surveyed, providing data for statistical analysis (refusal rate was 6.5%). Depicted in Table 1 are sociodemographic characteristics of surveyed women. Of women, 74.4% (n = 5,391) who were sexuality active with their partners. Those sexually inactive (n = 1,852; 25.6%) were significantly older, were less educated, were less healthy, used less HT, were married at a lower rate, and were postmenopausal in a higher rate. Within this group, 16.4% of partners had male SD (erectile dysfunction and/or premature ejaculation). The sexual activity rate significantly decreased with age: 85.4%, 40-44 years; 78.2%, 45-49 years; 74.3%, 50-53 years; and 56.0%, 55-59 years. Mean  $\pm$  SD age of sexually active women was 48.2  $\pm$  5.5 years; they had 11.9 years of schooling in average, 64.8% were married, 41.3% were postmenopausal, and 15.0% used HT. The percentage of women with a history of sexual abuse (rape) was 4.6%, with no significant difference seen regarding sexual activity status.

Epidemiological characteristics of sexually active women according to REDLINC center is presented in Table 2. A wide variation in these characteristics was seen. The refusal rate to

TABLE 1. Characteristics of sexually and nonsexually active women (N = 7,243)

	No. women (%)	Age, mean $\pm$ SD, y	Education, mean $\pm$ SD, y	% Married	% Postmenopausal <sup>a</sup>	% HT use	% Rape	% Healthy	% Partner with SD
All	7,243 (100.0)	49.0 $\pm$ 5.7	11.6 $\pm$ .4	55.1	46.8	14.1	4.6	90.4	24.4
Sexually inactive	1,852 (25.6)	51.3 $\pm$ 5.7	11.0 $\pm$ 4.7	26.7	62.7	11.6	4.5	88.3	16.4
Sexually active	5,391 (74.4)	48.2 $\pm$ 5.5	11.9 $\pm$ 4.3	64.8	41.3	15.0	4.7	91.2	27.1
<i>P</i> values according to $\chi^2$ or ANOVA	—	0.0001	0.0001	0.0001	0.0001	0.0002	NS	0.0003	0.0001

HT, hormone therapy; SD, sexual dysfunction; ANOVA, analysis of variance.

<sup>a</sup>Included natural and surgical.

AQ9

AQ10

AQ8

T1

AQ2

T2

TABLE 2. Epidemiological characteristics of women with sexual activity according to participating REDLINC center (n = 5,391)

Centers	% Women refusing to participate	% Women with sexual activity	Age, mean $\pm$ SD, y	Education, mean $\pm$ SD, y	% Married	% Postmenopausal	% HT	% Rape	% Healthy	% Partner with SD
Argentina										
Buenos Aires	12.4	81.3	50.1 $\pm$ 5.8	11.8 $\pm$ 4.6	60.4	52.9	8.8	2.6	97.4	23.4
Bolivia										
Cochabamba I	6.8	84.7	49.7 $\pm$ 4.9	13.9 $\pm$ 2.8	52.5	48.1	26.4	14.0	96.3	33.2
Cochabamba II	9.7	66.6	47.2 $\pm$ 5.8	14.5 $\pm$ 2.8	85.0	26.5	1.6	8.3	89.7	45.8
Santa Cruz	6.7	71.0	47.1 $\pm$ 5.5	13.2 $\pm$ 3.6	75.8	34.0	35.1	4.2	95.8	33.6
Colombia										
Bogota I	6.8	54.7	46.9 $\pm$ 5.3	9.2 $\pm$ 4.7	50.9	26.9	11.1	3.7	84.3	26.9
Bogota II	9.9	82.8	46.4 $\pm$ 4.7	7.4 $\pm$ 3.8	41.6	26.8	4.1	6.2	72.7	41.4
Cartagena	2.4	70.8	47.0 $\pm$ 5.8	7.9 $\pm$ 3.5	36.3	34.8	6.7	3.4	91.8	10.9
Chile										
Santiago de Chile	11.4	66.8	48.1 $\pm$ 5.6	10.9 $\pm$ 3.3	64.4	36.0	6.1	11.7	94.7	30.4
Cuba										
La Habana	1.9	76.9	47.8 $\pm$ 5.2	13.4 $\pm$ 3.0	54.7	43.3	4.5	0.3	87.5	21.1
Ecuador										
Quito	2.4	72.0	48.6 $\pm$ 5.4	12.8 $\pm$ 4.4	80.0	41.5	18.5	3.3	94.2	29.8
Guayaquil I	7.7	74.7	47.1 $\pm$ 5.3	13.2 $\pm$ 3.4	76.9	35.5	18.6	1.7	90.7	21.4
Guayaquil II	8.7	73.3	46.8 $\pm$ 5.1	14.9 $\pm$ 4.5	74.0	32.9	15.9	3.6	92.8	29.2
Panama										
Panama City	6.1	76.0	47.7 $\pm$ 5.3	13.0 $\pm$ 4.0	53.8	43.9	15.3	9.3	95.3	32.6
Peru										
Lima	4.2	73.7	48.5 $\pm$ 4.7	10.5 $\pm$ 3.3	68.6	43.6	10.4	6.1	91.4	18.9
Piura	5.0	80.0	49.5 $\pm$ 5.2	10.4 $\pm$ 3.5	80.3	46.6	16.6	0.0	98.5	20.0
Cuzco	7.0	74.6	47.2 $\pm$ 5.2	13.2 $\pm$ 3.4	77.1	35.4	18.8	1.7	90.6	21.2
Dominican Republic										
Santiago de los Caballeros	8.7	66.3	47.3 $\pm$ 5.1	11.2 $\pm$ 5.3	59.9	41.3	8.3	4.0	80.6	22.2
Uruguay										
Montevideo	3.4	81.1	52.2 $\pm$ 4.1	13.2 $\pm$ 3.8	76.6	74.4	39.0	2.6	99.7	23.1
Venezuela										
Caracas	2.4	53.4	48.7 $\pm$ 5.9	11.4 $\pm$ 4.5	63.1	55.2	15.8	2.5	96.6	30.0
<i>P</i> values <sup>a</sup> according to $\chi^2$ or ANOVA	0.0001	0.0001	0.0001	0.0001	0.0001	0.0001	0.0001	0.0001	0.0001	0.0001

REDLINC, Collaborative Group for Research of the Climacteric in Latin America; HT, hormone therapy; SD, sexual dysfunction; ANOVA, analysis of variance.

<sup>a</sup>Comparison between different centers.

participate varied from 12.4% in Buenos Aires (Argentina) to 1.9% in La Habana (Cuba). In addition, 53.4% of women in Caracas (Venezuela) were sexually active, whereas in Cochabamba I (Bolivia), 84.7% were active ( $P < 0.0001$ ). Mean  $\pm$  SD age in Bogota (Center II) was 46.4  $\pm$  4.7 years, whereas in Montevideo, this was 52.2  $\pm$  4.1 years ( $P < 0.0001$ ). Similar differences were found regarding educational level and rate of married status, postmenopause status, HT use, healthiness, history of rape, and partners with SD.

FSFI scores (total and per domain) for sexually active women according to participating center are depicted in Table 3. Mean  $\pm$  SD total FSFI score (whole sample) was 25.2  $\pm$  5.9, varying from 29.9  $\pm$  4.3 (Cartagena de Indias, Colombia) to 20.6  $\pm$  3.0 (Quito, Ecuador). The desire domain had the lowest score (most affected), with a mean score of 3.6  $\pm$  1.2 (maximum of 6), also widely varying among different centers: from 4.5  $\pm$  1.0 in Cartagena de Indias, Colombia, to 3.1  $\pm$  1.1 in Cochabamba, Bolivia (Center I). The Cartagena Colombian group was the center with less psychological compromise according to the MRS as compared with the Bolivian Cochabamba I center (score 2.9  $\pm$  2.7 vs 4.8  $\pm$  3.9;  $P < 0.0001$ ).

Pain and arousal domains were also affected, with mean  $\pm$  SD scores of 4.2  $\pm$  1.5 and 4.2  $\pm$  1.3, respectively. A wide variation in scores between groups was also observed, especially in the pain domain (ie, 5.0  $\pm$  1.1 in Cartagena de Indias, Colombia, and Panama City, Panama, compared with 1.9  $\pm$  1.0 in Montevideo, Uruguay). The satisfaction domain was the least affected, with a mean  $\pm$  SD score of 4.5  $\pm$  1.3, with the highest score seen in women of Cartagena de Indias, Colombia, and the lowest score (more impaired) in Cochabamba, Bolivia (Center I).

The total FSFI score allows definition of SD. In the whole Latin American cohort, 56.8% of them presented SD (FSFI score  $\leq 26.55$ ), with a prevalence varying from 21.0% to 98.5% depending on the center studied (Table 3). It is interesting that in the same city of Cochabamba, Bolivia, SD prevalence widely differed (86.3% in Cochabamba I vs 42.3% in Cochabamba II). Significant differences in epidemiological characteristics were observed between these two Bolivian centers, as one can see in Table 2. Women from Cochabamba I were older (49.7  $\pm$  4.9 vs 47.2  $\pm$  5.8 y; Mann-Whitney,  $P < 0.0001$ ), with a higher postmenopausal rate (48.1% vs 26.5%;  $\chi^2$ ,  $P < 0.0001$ ), lower rate of married status (52.5% vs 85.0%;

**TABLE 3.** FSFI scores (total and domain) and percentage of SD among sexually active women (n = 5,391) according to participating REDLINC Center

Centers	Desire	Arousal	Lubrication	Orgasm	Satisfaction	Pain	Total score	% SD
Argentina								
Buenos Aires	3.6 ± 1.2	4.0 ± 1.3	3.8 ± 1.4	3.7 ± 1.1	4.3 ± 1.3	3.4 ± 1.6	22.8 ± 5.1	79.5
Bolivia								
Cochabamba I	3.1 ± 1.1	3.0 ± 1.1	3.7 ± 1.0	3.5 ± 1.1	3.3 ± 1.2	4.1 ± 1.0	20.7 ± 5.2	86.3
Cochabamba II	3.6 ± 1.4	4.2 ± 1.4	4.6 ± 1.3	4.7 ± 1.2	4.9 ± 1.1	5.0 ± 1.1	27.2 ± 6.8	42.3
Santa Cruz	3.8 ± 1.0	4.1 ± 1.2	3.8 ± 1.0	3.8 ± 1.2	3.8 ± 1.4	3.3 ± 1.3	22.6 ± 4.5	87.9
Colombia								
Bogota I	3.8 ± 1.2	4.3 ± 1.2	4.3 ± 1.2	4.3 ± 1.2	4.5 ± 1.3	4.2 ± 1.5	25.4 ± 5.8	58.3
Bogota II	3.5 ± 1.0	4.0 ± 1.0	4.7 ± 1.1	4.5 ± 1.1	4.6 ± 1.2	4.7 ± 1.2	26.0 ± 4.6	50.3
Cartagena	4.5 ± 1.0	4.7 ± 0.9	5.3 ± 0.9	5.3 ± 0.9	5.1 ± 1.0	5.0 ± 1.1	29.9 ± 4.3	21.0
Chile								
Santiago de Chile	4.0 ± 1.2	4.6 ± 1.0	4.8 ± 1.2	4.8 ± 1.2	4.9 ± 1.1	4.8 ± 1.2	27.8 ± 5.1	36.0
Cuba								
La Habana	3.8 ± 1.3	4.4 ± 1.4	4.9 ± 1.3	4.7 ± 1.4	4.4 ± 1.6	4.9 ± 1.5	27.1 ± 6.7	33.2
Ecuador								
Quito	3.1 ± 0.8	3.6 ± 1.1	3.4 ± 0.6	3.6 ± 0.9	4.2 ± 1.4	2.7 ± 1.3	20.6 ± 3.0	98.5
Guayaquil I	3.5 ± 1.2	4.0 ± 1.4	4.6 ± 1.2	4.3 ± 1.2	4.3 ± 1.3	4.5 ± 1.2	25.1 ± 6.1	55.2
Guayaquil II	3.8 ± 1.1	4.3 ± 1.2	4.9 ± 1.1	4.6 ± 1.2	4.7 ± 1.2	4.7 ± 1.3	27.0 ± 5.6	43.3
Panama								
Panama City	3.8 ± 1.1	4.1 ± 1.1	4.9 ± 1.1	4.7 ± 1.3	4.8 ± 1.2	5.0 ± 1.1	27.2 ± 5.1	40.9
Peru								
Lima	3.6 ± 1.4	3.8 ± 1.4	4.1 ± 1.4	3.9 ± 1.3	4.1 ± 1.3	3.6 ± 1.5	23.1 ± 7.1	71.8
Piura	3.6 ± 0.8	4.7 ± 0.5	4.7 ± 0.9	3.8 ± 0.7	4.4 ± 0.7	5.0 ± 0.9	26.2 ± 3.5	32.1
Cuzco	3.5 ± 1.2	4.0 ± 1.4	4.6 ± 1.2	4.3 ± 1.2	4.3 ± 1.4	4.5 ± 1.2	25.2 ± 6.1	54.9
Dominican Republic								
Santiago de los Caballeros	3.7 ± 1.2	4.4 ± 1.3	4.7 ± 1.2	4.5 ± 1.3	4.7 ± 1.3	4.8 ± 1.2	26.9 ± 6.0	43.7
Uruguay								
Montevideo	3.7 ± 1.2	4.5 ± 1.2	3.5 ± 0.5	3.8 ± 0.7	4.8 ± 1.2	1.9 ± 1.0	22.2 ± 3.5	94.5
Venezuela								
Caracas	3.7 ± 1.3	4.3 ± 1.3	4.6 ± 1.3	4.6 ± 1.3	4.6 ± 1.3	4.7 ± 1.3	26.5 ± 6.2	44.3
<i>P</i> value <sup>a</sup> according to Student's <i>t</i> test or ANOVA	0.0001	0.0001	0.0001	0.0001	0.0001	0.0001	0.0001	0.0001
All	3.6 ± 1.2	4.2 ± 1.3	4.4 ± 1.2	4.3 ± 1.2	4.5 ± 1.3	4.2 ± 1.5	25.2 ± 5.9	56.8

Values are expressed in mean ± SD, unless otherwise stated. FSFI, Female Sexual Function Index; REDLINC, Collaborative Group for Research of the Climacteric in Latin America; SD, sexual dysfunction; ANOVA, analysis of variance.

<sup>a</sup>Comparison between different centers.

$\chi^2$ ,  $P < 0.0001$ ), and less education ( $13.9 \pm 2.8$  vs  $14.5 \pm 8.8$  y; Student's *t* test,  $P < 0.0005$ ). HT use was extremely different between these two centers (26.4% vs 1.6%;  $\chi^2$ ,  $P < 0.0001$ ).

To assess factors that could explain differences in the prevalence of SD among different populations, centers were grouped into terciles (according to the mean ± SD prevalence; Table 4). The tercile with higher SD prevalence (86.4%, mean) compared with that with less SD (32.2%) had significantly older women ( $49.5 \pm 5.3$  vs  $48.0 \pm 5.6$  y; Student's *t* test,  $P < 0.0001$ ) and older partners ( $53.0 \pm 6.9$  vs  $50.2 \pm 7.5$  y; Mann-Whitney,  $P < 0.0001$ ). Similarly, there was a significantly higher rate of married (68.5% vs 63.1%;  $\chi^2$ ,  $P < 0.0008$ ), postmenopausal (49.7% vs 39.3%;  $\chi^2$ ,  $P < 0.0001$ ), and HT-using women (23.0% vs 9.2%;  $\chi^2$ ,  $P < 0.0001$ ). It was observed that those centers with higher SD rates had women with lower lubrication according to the MRS (60.4% vs 40.8;  $P < 0.0001$ ), with no differences regarding refusal rate to answer the survey, their health perception, history of oophorectomy, rape, and partner SD rate (27% vs 26.2%). Aiming to have some evidence that the aforementioned predicting variables are associated with participating cities with higher SD prevalence, we performed one logistic regression model in which indicator variables for just the cities as predictors were entered, and subsequently, other predictors

were added one by one and then all together. It was observed that when other variables were entered, odds ratio (OR) for SD dropped in cities with higher SD rate from 12.26 (95% CI, 10.36-14.51) to 3.41 (95% CI, 2.56-4.54), providing some evidence that the added predictors explain the associations with cities. As expected, the total FSFI score was significantly lower in the tercile with higher SD prevalence ( $22.0 \pm 5.0$  vs  $27.5 \pm 5.4$ ).

After adjusting for confounding factors, logistic regression analysis (Table 5) determined that main factors associated with SD were bad lubrication as assessed with the MRS (OR, 3.86; 95% CI, 3.37-4.43), use of alternative menopausal therapies (OR, 2.13; 95% CI, 1.60-2.84), partner sexual failure or dysfunction (erectile dysfunction and/or precocious ejaculation; OR, 1.89; 95% CI, 1.63-2.20), older women (age >48 y; OR, 1.84; 95% CI, 1.61-2.09), bladder problems (OR, 1.47; 95% CI, 1.28-1.69), HT use (OR, 1.39; 95% CI, 1.15-1.68), negative perception on female health status (OR, 1.31; 95% CI, 1.05-1.64), and being married (OR, 1.22; 95% CI, 1.07-1.40). Protective factors for SD were higher female educational level (OR, 0.75; 95% CI, 0.66-0.86), partner faithfulness (OR, 0.66; 95% CI, 0.59-0.73), and having access to a private healthcare system (OR, 0.56; 95% CI, 0.49-0.64). Other menopausal symptoms comprising the

**TABLE 4.** Comparison of centers with lowest and highest SD prevalence (sexually active, n = 5,391)

Centres	%SD
Cartagena	21.0
Piura	32.1
La Habana	33.2
Santiago	36.0
Panama	40.9
Cochabamba II	42.3
Guayaquil II	43.3
Dominican Rep.	43.7
Caracas	44.3
Bogota II	50.3
Cuzco	54.9
Guayaquil I	55.2
Bogota I	58.3
Lima	71.8
Buenos Aires	79.5
Cochabamba I	86.3
Santa Cruz	87.9
Montevideo	94.5
Quito	98.5
<b>TOTAL</b>	<b>56.8</b>

1<sup>st</sup> Tercile: (Lower SD prevalence)

**Women of within group of higher SD prevalence were significantly (p<0.001):**

- older (49.5±5.3 vs. 48.0±5.6 years)
- had an older partner (53.0±6.9 vs. 50.2±7.5 years)
- had higher rates of:
  - married status (68.5% vs. 63.1%)
  - postmenopausal status (49.7% vs. 39.3%)
  - HT use (23% vs. 9.2%)
  - Vaginal dryness (MRS, 60.4% vs. 40.8%)

3<sup>rd</sup> Tercile: (Higher SD prevalence)

SD, sexual dysfunction; HT, hormonal therapy; MRS, Menopause Rating Scale.

MRS (except bladder problems) as well as a history of sexual abuse, church attendance, partner older age, or alcoholism were not associated with SD risk.

## DISCUSSION

An important issue raised during the planning of the present cross-sectional study on middle-aged women was deciding whether analysis should be confined to all or only to those who were sexually active. Sexual inactivity rate among middle-aged women is high in various reports. Indeed, 34% of European women aged 40 to 80 years<sup>24</sup> and 38.4% of US women aged 57 to 64 years<sup>25</sup> reported being sexually inactive 1 year before the survey. As for Latin America, a Chilean study found that 20.8% of women aged 40 to 64 years were not sexually active.<sup>26</sup> Hence, a concern that arises with studies addressing sexuality is that exclusion of sexually inactive women from analysis would also exclude an important population segment, which could, in fact, present SD, the latter being the cause of sexual inactivity. This possibility seems to be the case in a study that points out that 70% of middle-aged sexually inactive women have a partner and that the main reason for their not having sex is they present female SD.<sup>27</sup> In light of this evidence and of the fact that the FSFI is a test designed for and validated on sexually active women, we therefore decided to focus our analysis on sexually active women. Nevertheless, epidemiological characteristics of nonsexually active ones were described as well.

In the present series, compared with sexually active women, inactive ones were older, were less educated, and had worse perception of their health status; also more were postmeno-

pausal, fewer were married, and fewer used HT. All these variables constitute SD risk factors.<sup>28-30</sup> Therefore, a high prevalence of sexual disorders among them would not be rare.

The percentage of sexual activity in the present series varied widely among the centers studied: for instance, from 84.7% in Cochabamba I (Bolivia) to 53.4% in Caracas (Venezuela). Overall, 74.4% of the women in our series were sexually active. This rate is higher than the rate previously reported for Europe and United States.<sup>24,25</sup> However, comparisons are difficult because the targeted age group and length of time used to define sexual inactivity may in fact vary from one study to another. One study that allows comparing sexual activity rates in different regions of the world is the Global Study of Sexual Attitudes and Behaviors,

**TABLE 5.** Main factors associated with sexual dysfunction in sexually active women (n = 5,391): logistic regression analysis

Factors	OR	95% CI	P
<b>Female</b>			
Bad lubrication	3.86	3.37-4.43	0.0001
Use of alternative therapies	2.13	1.60-2.84	0.0001
Older age (>48 y)	1.84	1.61-2.09	0.0001
Bladder problems	1.47	1.28-1.69	0.0001
Hormonal therapy use	1.39	1.15-1.68	0.0001
Negative perception on female health status	1.31	1.05-1.64	0.0017
Being married	1.22	1.07-1.40	0.0030
Education >12 y	0.75	0.66-0.86	0.0001
Access to private healthcare system	0.56	0.49-0.64	0.0001
<b>Partner</b>			
Sexual failure	1.89	1.63-2.20	0.0001
Faithfulness	0.66	0.59-0.73	0.0001

OR, odds ratio.

which analyzed 13,882 women aged 40 to 80 years in 29 countries and found that 65% of surveyed women had sexual intercourse in the previous year<sup>31</sup>; the higher rate of sexual inactivity compared with that in our series (35% vs 25.6%) could have been determined by the fact that older women were included and related to the epidemiological aging profile of each country. Our series only included women aged 40 to 59 years, displaying a sexual activity rate dropping from 85.4% in women aged 40 to 44 years to 56% in those aged 55 to 59 years. Including only middle-aged women decreases selection bias caused by older women, which eventually influences sexual activity rate.

In the present series, the mean total FSFI score ( $n = 5,391$ ) was 25.2, immediately suggesting a high SD prevalence because this score is below 26.55, the FSFI cutoff value used for defining SD.<sup>20</sup> Mean total FSFI scores varied among centers from 20 to 30, suggesting significant population differences. Our average total FSFI score was slightly higher than that reported by others: 20.4 in Thailand (women's age range, 45-55 y),<sup>32</sup> 24.2 in Turkey (mean age, 38.6 y),<sup>33</sup> and 25 in Italy (women's age range, 45-65 y)<sup>34</sup>; however, it was lower than that reported by Rozen et al<sup>4</sup>, which was 30.5, among women without SD. In Chile, we have previously reported scores ranging from 27.3 to 19.3 among women aged 45 to 49 and 60 to 64 years, respectively.<sup>35</sup> Although the FSFI has been widely used to study the impact of several diseases and therapies on sexuality, few epidemiological studies have been drawn on normal populations.

Assessment of sexuality and the diagnosis of SD have never been exempt from controversy. For instance, the Food and Drug Administration has assumed a more endpoint position, suggesting the quantification of orgasms or number of occurrences of sexual intercourse. Despite this, good sexuality is not determined by the number of events, but rather by women's perceptions and satisfaction. For this reason, self-administered questionnaires such as the FSFI have been suggested as being ideal for sexual assessment and diagnosing SD.<sup>36</sup> Nevertheless, sexual disorder prevalence will widely vary according to the tool used.<sup>37</sup> Using the FSFI, SD prevalence varied widely among the centers of the present study, with overall 56.8% of women being affected. Although our results cannot be extrapolated to all Latin America, the high participation rate (low refusal rate) within all cities gives strength to the findings of this cross-sectional study. Our SD prevalence rate (56.8%) is similar to that found by others using the FSFI tool in Colombia (37.8%),<sup>13</sup> Iran (39%; 50-60 y),<sup>38</sup> and Greece (48.8%; 43 y on average),<sup>39</sup> yet lower than that found in Thailand (82.3%) for women aged 45 to 55 years.<sup>32</sup> Using another SD diagnostic tool, a multicenter study (29 countries) including 13,882 women aged 40 to 80 years detected that 39% present SD.<sup>40</sup> Applying different methodology, Laumann et al,<sup>41</sup> in a representative US population-based study, have also reported that 43% of women aged 18 to 59 years present SD.

Desire was the most compromised sexual domain of our series, a situation that correlates with many other stud-

ies.<sup>28,33,40,42-45</sup> An interesting finding was that the group with better FSFI desire scores (Cartagena de Indias) was the same group presenting lower psychological MRS scores, suggesting some type of relation between sexual desire and psychological symptoms. This correlation has been previously found in a representative North American population-based study pointing out that decreased sexual desire is associated with emotional psychological distress.<sup>46</sup> Our series found, according to the FSFI, that the arousal domain is also compromised. Anhedonia, the incapacity to experience pleasure from normally pleasurable life events such as eating, exercise, and social or sexual interaction, is recognized as a key symptom in mood disorder, a frequent problem in climacteric women.<sup>47</sup>

The least affected of all sexual domains in the present series was satisfaction (higher total score), with an average score of 4.5 for all studied centers. These results seem to confirm those of other studies, suggesting that the presence of sexual problems does not affect female sexuality as a whole and stressing the importance of individual perceptions when defining SD.<sup>39</sup> However, one concern that arises is the following question: can we diagnose SD based on the FSFI score, given the high rate of sexual satisfaction found in these women? One hypothesis could be that Latin American women deny accepting the fact that impaired sexuality is really a significant problem in their relationship. This interpretation seems to be supported by observations found in studies drawn from other similar Latin populations. A French study pointing out the fact that 83% of individuals, independently of their gender, are satisfied with their sexuality found that 70% of the men and 55% of the women would like some changes in their sexual lives, somehow reflecting a certain degree of dissatisfaction.<sup>48</sup> Probably with another type of survey, such as that performed in the French study, we could have revealed a higher rate of sexual dissatisfaction among our participants.

The wide variability of SD prevalence found in the present series immediately suggests that this could be the result of ethnical and cultural diversity and socioeconomical differences found in Latin America. Moreover, the marked difference in SD prevalence found in two different groups of the same city (ie, 86.3% in Cochabamba I vs 42.3% in Cochabamba II) suggests the importance of individual risk factors for sexual disorders. The Cochabamba I group was composed of older women, with lower educational level and married status and higher rates of being menopausal and HT use. The same trend was found in a comparison of centers with higher SD rates: older age, higher rates of postmenopause status, and vaginal lubrication problems.

Our regression model found that the main risk factor for SD in middle-aged women was poor vaginal lubrication, implicating an organic cause and not a psychological one. Decreased lubrication is associated with unpleasant sensations and pain, which significantly affects female sexuality, even in younger women.<sup>49</sup> That an organic cause was a strong risk factor could have prognostic and therapeutic

implications because local or systemic estrogenic therapy improves vaginal lubrication significantly and hence influences sexual function.<sup>50,51</sup> Despite this, our regression model found HT as a risk factor, a fact that does not necessarily contradict the positive impact of HT on sexuality. Women who seek therapy are logically those with more symptoms, and although HT improves sexuality, complete achievement may not necessarily ensue, especially if compliance is not optimal. In the present series, women using HT presented a 1.39 OR increase for SD, which was lower than the two-fold increase found among those using alternate therapies.

Higher educational level and access to paid healthcare systems (indirect indicators of socioeconomic level) seemed to be SD protective factors. This observation has been a constant in several studies, independent of the place of origin. Safarinejad,<sup>38</sup> using the FSFI tool, found that in Iranian women aged 20 to 60 years, educational level is an SD protective factor. Age and educational level were also found to be risk factors for SD in a representative US study composed of women aged 18 to 59 years.<sup>41</sup> Similar results have been described in other countries such as Brazil<sup>28</sup> and Turkey.<sup>33</sup> Because educational level in Latin America is experiencing an overall increasing trend,<sup>52</sup> it can be expected that this will have a midterm positive impact on sexuality.

As expected, our series found that the partner also exerts an important influence over female sexuality. Indeed, masculine SD significantly increased the risk for female SD. In a worldwide series regarding SD, it was found that premature ejaculation and erectile dysfunction affected 10% and 14% of male partners aged 40 to 80 years, respectively,<sup>40</sup> a rate similar to that found in the present series (24.4%). Another publication from the same study determined that 63% of women were not very satisfied with the hardness of their partner's erection and that this issue influenced their sexual satisfaction.<sup>53</sup> This is a very important issue because male SD is a modifiable factor that, with appropriate therapy, may significantly improve female sexuality. A study showed that treating erectile dysfunction significantly improved arousal, lubrication, pain, orgasm indices, and women's satisfaction.<sup>54</sup> In addition, our series found that partner faithfulness significantly decreased SD; this may translate to a healthy relationship, a known factor related to good sexuality.<sup>55,56</sup> One would expect male SD to increase with age; however, partner older age was not found as a risk factor for SD in our series. It is possible that partner SD is not only related to age but also to other factors, which are not the focus of the present report. However, high sexual self-esteem, good health, and an active sexual history have been related to male sexual activity.<sup>57</sup>

In other series, sexual abuse has been found as a significant risk factor for SD in middle-aged women<sup>27</sup>; this was not the case in our series in which the rate of sexual abuse did not significantly differ among women with or without SD. Other studies also using the FSFI have not found higher rates of SD among sexually assaulted women.<sup>58,59</sup> Regular church attendance was not found as a protective factor for SD, a fact that correlates with other series.<sup>12,60</sup>

Finally, one limitation of the present study is its cross-sectional nature. However, the great amount of data regarding this middle-aged female series and their sociodemographic background and their partners constitutes an important referral tool for other Hispanic populations, not to mention the consequently important increase in scientific information and contributions. Not determining body mass index (overweight and obesity) in the present series may be seen as another important drawback, particularly if obesity was been found by others to be a female SD determinant.<sup>61,62</sup>

## CONCLUSIONS

In conclusion, in this Latin American middle-aged series, the prevalence of SD was found to be high, varying widely in different populations. Decrease in vaginal lubrication was the most important associated risk factor. Differences in the prevalence of risk factors among groups could explain the variation of SD prevalence observed in this study. Hence, because of the wide diversity of the population (educational level, marital status, geographical location, habits, etc), findings cannot be generalized to one Latin American country or population. Despite the outlined limitations, to the best of our knowledge this is the first and largest study assessing sexuality in a Latin American climacteric series in which SD risk factors, which are described some of modifiable.

## REFERENCES

1. World Health Organization (WHO). *Defining Sexual Health: Report of a Technical Consultation on Sexual Health*. WHO: Geneva, 2006.
2. CEPAL. Anuario estadístico de América Latina y el Caribe. 2007. Available at: [http://www.eclaccl/publicaciones/xml/8/32598/LCG2356B\\_1.pdf](http://www.eclaccl/publicaciones/xml/8/32598/LCG2356B_1.pdf). Accessed November 12, 2008.
3. Basson R, Berman J, Burnett A, et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. *J Urol* 2000;163:888-894.
4. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. *J Sex Marital Ther* 2000;26:191-208.
5. Blümel JE, Binfa L, Cataldo L, Carrasco A, Izaguirre H, Sarra S. Índice de función sexual femenina: un test para evaluar la sexualidad de la mujer. *Rev Chil Obstet Ginecol* 2004;69:118-125.
6. Mezones-Holguin E, Blümel JE, Huevo M, et al. Impact of diabetes mellitus on the sexuality of Peruvian postmenopausal. *Gynecol Endocrinol* 2008;24:470-474.
7. Monterrosa A, Blümel JE, Chedraui P. Increased menopausal symptoms among Afro-Colombian women as assessed with the Menopause Rating Scale. *Maturitas* 2008;59:182-190.
8. Royer M, Castelo-Branco C, Blümel JE, et al. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women. *Climacteric* 2007;10:164-170.
9. Castelo-Branco C, Blümel JE, Chedraui P, et al. Age at menopause in Latin America. *Menopause* 2006;13:706-712.
10. Chedraui P, Blümel JE, Baron G, et al. Impaired quality of life among middle aged women: a multicentre Latin American study. *Maturitas* 2008;61:323-329.
11. CEPAL-ECLAC. *Statistical Yearbook for Latin America and the Caribbean*. Santiago, Chile: United Nations, 2003.
12. Blümel JE, Araya H, Riquelme R, Castro G, Sanchez F, Gramegna G. Prevalence of sexual dysfunction in climacteric women. Influence of menopause and hormone replace therapy. *Rev Med Chil* 2002;130:1131-1138.
13. Garcia S, Moreno S, Aponte H. Prevalence of sexual dysfunction in

AQ14

AQ15

- female outpatients and personnel at a Colombian hospital: correlation with hormonal profile. *J Sex Med* 2008;5:1208-1213.
14. Tracy JK, Junginger J. Correlates of lesbian sexual functioning. *J Womens Health (Larchmt)* 2007;16:499-509.
  15. CEPAL. *Panorama Social de América Latina*. Santiago, Chile: CEPAL, 2003:66.
  16. Brett KM, Chong Y. *Hormone Replacement Therapy: Knowledge and Use in the United States*. Hyattsville, MD: National Center for Health Statistics, 2001.
  17. NIH consensus conference. Impotence. NIH consensus development panel on impotence. *JAMA* 1993;270:83-90.
  18. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, 4th ed. Washington, DC: American Psychiatric Association, 2000.
  19. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). *Climacteric* 2001;4:267-272.
  20. Wiegel M, Meston C, Rosen R. The Female Sexual Function Index (FSFI): cross-validation and development of clinical cutoff scores. *J Sex Marital Ther* 2005;31:1-20.
  21. Heinemann LA, Potthoff P, Schneider HP. International versions of the Menopause Rating Scale (MRS). *Health Qual Life Outcomes* 2003;1:28.
  22. Chedraui P, Aguirre W, Hidalgo L, Fayad L. Assessing menopausal symptoms among healthy middle aged women with the Menopause Rating Scale. *Maturitas* 2007;57:271-278.
  23. Aedo S, Porcile A, Iribarra C. Calidad de vida relacionada con el climaterio en una población Chilena de mujeres saludables. *Rev Chil Obstet Ginecol* 2006;71:402-409.
  24. Nicolosi A, Buvat J, Glasser DB, et al. Sexual behaviour, sexual dysfunctions and related help seeking patterns in middle-aged and elderly Europeans: the Global Study of Sexual Attitudes and Behaviors. *World J Urol* 2006;24:423-428.
  25. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muirheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. *N Engl J Med* 2007;357:762-774.
  26. Castelo-Branco C, Blümel JE, Araya H, et al. Prevalence of sexual dysfunction in a cohort of middle-aged women: influences of menopause and hormone replacement therapy. *J Obstet Gynaecol* 2003;23:426-430.
  27. Blümel JE, Castelo-Branco C, Cancelo MJ, Romero H, Aprikian D, Sarra S. Impairment of sexual activity in middle-aged women in Chile. *Menopause* 2004;11:78-81.
  28. Abdo CH, Oliveira WM Jr, Moreira ED Jr, Fittipaldi JA. Prevalence of sexual dysfunctions and correlated conditions in a sample of Brazilian women—results of the Brazilian study on sexual behavior (BSSB). *Int J Impot Res* 2004;16:160-166.
  29. Addis IB, Van Den Eeden SK, Wassel-Fyr CL, et al. Sexual activity and function in middle-aged and older women. *Obstet Gynecol* 2006;107:755-764.
  30. Lewis RW, Fugl-Meyer KS, Bosch R, et al. Epidemiology/risk factors of sexual dysfunction. *J Sex Med* 2004;1:35-39.
  31. Laumann EO, Nicolosi A, Glasser DB, et al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. *Int J Impot Res* 2005;17:39-57.
  32. Peeyananjarassri K, Liabsuetrakul T, Soonthornpun K, Choobun T, Manopsilp P. Sexual functioning in postmenopausal women not taking hormone therapy in the Gynecological and Menopause Clinic, Songklanagarind Hospital measured by Female Sexual Function Index questionnaire. *J Med Assoc Thai* 2008;91:625-632.
  33. Aslan E, Beji NK, Gungor I, Kadioglu A, Dikencik BK. Prevalence and risk factors for low sexual function in women: a study of 1,009 women in an outpatient clinic of a university hospital in Istanbul. *J Sex Med* 2008;5:2044-2052.
  34. Nappi RE, Albani F, Vaccaro P, et al. Use of the Italian translation of the Female Sexual Function Index (FSFI) in routine gynecological practice. *Gynecol Endocrinol* 2008;24:214-219.
  35. Blümel JE, Bravo F, Recavarren M, Sarra S. Sexual function in postmenopausal women using hormone replacement therapy. *Rev Med Chil* 2003;131:1251-1255.
  36. Althof SE, Rosen RC, DeRogatis L, Corty E, Quirk F, Symonds T. Outcome measurement in female sexual dysfunction clinical trials: review and recommendations. *J Sex Marital Ther* 2005;31:153-166.
  37. Hayes RD, Dennerstein L, Bennett CM, Fairley CK. What is the "true" prevalence of female sexual dysfunctions and does the way we assess these conditions have an impact? *J Sex Med* 2008;5:777-787.
  38. Safarinejad MR. Female sexual dysfunction in a population-based study in Iran: prevalence and associated risk factors. *Int J Impot Res* 2006;18:382-395.
  39. Ferenidou F, Kapoteli V, Moisisidis K, Koutsogiannis I, Giakoumelos A, Hatzichristou D. Presence of a sexual problem may not affect women's satisfaction from their sexual function. *J Sex Med* 2008;5:631-639.
  40. Nicolosi A, Laumann EO, Glasser DB, et al. Sexual behavior and sexual dysfunctions after age 40: the Global Study of Sexual Attitudes and Behaviors. *Urology* 2004;64:991-997.
  41. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States. Prevalence and predictors. *JAMA* 1999;281:537-544.
  42. Nobre PJ, Pinto-Gouveia J, Gomes FA. Prevalence and comorbidity of sexual dysfunctions in a Portuguese clinical sample. *J Sex Marital Ther* 2006;32:173-182.
  43. Hayes RD, Bennett CM, Fairley CK, Dennerstein L. What can prevalence studies tell us about female sexual difficulty and dysfunction? *J Sex Med* 2006;3:589-595.
  44. Ventegodt S. Sex and the quality of life in Denmark. *Arch Sex Behav* 1998;27:295-307.
  45. Oksuz E, Malhan S. Prevalence and risk factors for female sexual dysfunction in Turkish women. *J Urol* 2006;175:654-658.
  46. Leiblum SR, Koochaki PE, Rodenberg CA, Barton IP, Rosen RC. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). *Menopause* 2006;13:46-56.
  47. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. *Arch Gen Psychiatry* 2006;63:375-382.
  48. Colson MH, Lemaire A, Pinton P, Hamidi K, Klein P. Sexual behaviors and mental perception, satisfaction and expectations of sex life in men and women in France. *J Sex Med* 2006;3:121-131.
  49. Farmer MA, Meston CM. Predictors of genital pain in young women. *Arch Sex Behav* 2007;36:831-843.
  50. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. *Cochrane Database Syst Rev* 2006;4:CD001500.
  51. Lara LA, Useche B, Ferriani RA, et al. The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response. *J Sex Med* 2009;6:30-39.
  52. Muñoz Izquierdo C, Márquez A. Indicadores del desarrollo educativo en América Latina y de su impacto en los niveles de vida de la población. *Rev Electron Investig Educ* 2000;2:77-97.
  53. Mulhall J, King R, Glina S, Hvidsten K. Importance of and satisfaction with sex among men and women worldwide: results of the global better sex survey. *J Sex Med* 2008;5:788-795.
  54. Cayan S, Bozlu M, Canpolat B, Akbay E. The assessment of sexual functions in women with male partners complaining of erectile dysfunction: does treatment of male sexual dysfunction improve female partner's sexual functions? *J Sex Marital Ther* 2004;30:333-341.
  55. Paiva V, Aranha F, Bastos FI. Grupo de Estudos em População, Sexualidade e Aids. [Opinions and attitudes regarding sexuality: Brazilian national research, 2005]. *Rev Saude Publica* 2008;42:54-64.
  56. Burleson MH, Trevathan WR, Todd M. In the mood for love or vice versa? Exploring the relations among sexual activity, physical affection, affect, and stress in the daily lives of mid-aged women. *Arch Sex Behav* 2007;36:357-368.
  57. Kontula O, Haavio-Mannila E. The impact of aging on human sexual activity and sexual desire. *J Sex Res* 2008;17:1-11.
  58. Rellini A, Meston C. Sexual function and satisfaction in adults based on the definition of child sexual abuse. *J Sex Med* 2007;4:1312-1321.
  59. Witting K, Santtila P, Jern P, et al. Evaluation of the Female Sexual Function Index in a population based sample from Finland. *Arch Sex Behav* 2008;37:912-924.
  60. Oberg K, Fugl-Meyer AR, Fugl-Meyer KS. On categorization and quantification of women's sexual dysfunctions: an epidemiological approach. *Int J Impot Res* 2004;16:261-269.
  61. Kolotkin RL, Binks M, Crosby RD, Østbye T, Gress RE, Adams TD. Obesity and sexual quality of life. *Obesity (Silver Spring)* 2006;14:472-479.
  62. Esposito K, Ciotola M, Giugliano F, et al. Association of body weight with sexual function in women. *Int J Impot Res* 2007;19:353-357.

## APPENDIX 1. Participating REDLINC countries and investigators

Country	City	Investigator(s)
Argentina	Buenos Aires	M. Royer
Bolivia	Cochabamba I	M.T. Espinoza
	Cochabamba II	E. Soto
	Santa Cruz	D. Mostajo
Colombia	Bogota I	G. Baron
	Bogota II	W. Onatra
	Cartagena	A. Monterrosa
Chile	Santiago de Chile	D. Flores
		J.E. Blümel
Cuba	La Habana	S. Vallejo
		D. Navarro
Ecuador	Quito	A. Calle
	Guayaquil I	P. Chedraui
	Guayaquil II	P. Leon-Leon
	Panama City	K. Tserota
Panama	Panama City	H. Izaguirre
		E. Mezones-Holguin
		E. Ojeda
		A. Bencosme
Dominican Republic	Santiago de los Caballeros	S. Lima
Uruguay	Montevideo	E. Belzares
Venezuela	Caracas	